GlassScriptPhysician profile
Ronald Sachs
NPI 1336254416
$1,671.26
in general payments reported to CMS, 2019-2025
13 companies · $762 in 2025
The $762 reported for 2025 was more than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.99 · 2020: $37.93 · 2021: $33.79 · 2022: $185 · 2023: $265 · 2024: $288 · 2025: $762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,314.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coherus Oncology, INC. | $268.35 | 2022-2023 | |
| Abbvie INC. | $258.16 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $244.08 | 2025 | Acthar |
| Sight Sciences, INC. | $140.65 | 2025 | Sion Surgical Instrument, Omni Surgical System |
| Apellis Pharmaceuticals, INC. | $127.70 | 2022-2025 | Syfovre |
| New World Medical,INC. | $125.41 | 2024 | Ahmed Glaucoma Valve, Clearpath, Kahook Dual Blade |
| Allergan, INC. | $125.00 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $114.97 | 2019-2020 | |
| Tarsus Pharmaceuticals, INC. | $113.88 | 2025 | Xdemvy |
| Alimera Sciences, INC. | $56.74 | 2020-2021 | |
| Astellas Pharma US INC | $47.70 | 2025 | Izervay |
| Harrow Eye, LLC | $35.27 | 2025 | Iheezo |
| Horizon Therapeutics Plc | $13.35 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Sachs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.